Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) have received approval from Japan’s Ministry of Health for Dupixent (dupilumab) as the first targeted therapy for adults with moderate-to-severe bullous pemphigoid, a rare skin disease. This approval is significant as it offers a new treatment option that could reduce reliance on long-term corticosteroids and immunosuppressants. The decision is backed by promising results from the LIBERTY-BP-ADEPT Phase 2/3 trial, which demonstrated that patients on Dupixent were over four times more likely to achieve sustained disease remission compared to those on placebo.
This development is expected to bolster Sanofi’s revenue, with Dupixent projected to generate €15.7 billion in global sales by 2025, marking a 25% increase from 2024. The U.S. market is anticipated to contribute significantly, driving growth as Dupixent continues to establish itself as a cornerstone therapy for type 2 inflammatory diseases.
For market professionals, the approval highlights Dupixent’s expanding role in Sanofi’s portfolio, potentially enhancing stock performance as investor confidence grows in the company’s ability to innovate and capture market share in specialty pharmaceuticals.
Source: nasdaq.com